Direct targeting of STAT3 by xanthatin suppresses allergic airway inflammation via inhibition of TSLP release and NK2 cell polarization

Key Points

• STAT3 inhibition leads to decreased allergic airway inflammation and is tied to xanthatin's effects.
• With xanthatin treatment, TSLP levels drop significantly, indicating a successful therapeutic mechanism.
• Analysis includes targeting the TSLP/STAT3 axis in epithelial cells to improve market prospects for asthma.
• This targeted therapy may enable new pathways for asthma management, calling for further testing of xanthatin.